The Antibacterial Action of Safranin and Gentian Violet

Falah AL-Khikani, Ph.D.1,2,* and Aalae Ayit, M.Sc.2

1Medical Technique Department, College of Medical Technique, The Islamic University, Babylon, Iraq; and 2Department of Microbiology, Al-Shomali General Hospital, Babylon, Iraq

ABSTRACT

Background: The increasing resistance of many bacterial pathogens against antibiotic measures urgently requires new or repurposing therapeutic strategies. Gentian violet is a triarylmethane dye used as a histological stain and for Gram’s method of classifying bacteria. It also exerts an antimicrobial effect against certain pathogens, especially dermatological infections. Safranin is the most popular counterstain used in medical laboratories due to its low cost and safe laboratory usage. However, few studies have been conducted on the antimicrobial activity of safranin.

Objective: With the growing prevalence of multidrug-resistant bacteria, this study aimed to evaluate the antibacterial efficacy of gentian violet and safranin against multidrug-resistant Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa).

Methods: All tested bacteria were multidrug-resistant (MDR) bacteria isolated from skin infections (abscesses and wounds). Using gentian violet and safranin, antibacterial effects were studied using the well-diffusion method against 20 samples of clinically isolated bacteria, 10 diagnosed as S. aureus, and 10 as P. aeruginosa. Bacteria were diagnosed using the VITEK 2 automated system (bioMérieux, Marcy-l’Étoile, France). Iodine served as the control agent, since both Gram-positive and Gram-negative bacteria are sensitive to it.

Results: Gentian violet dye has been shown to be 100% sensitive to both Gram-positive and Gram-negative bacterial isolates. Although safranin also had high sensitivity (100%) to S. aureus isolates, its sensitivity to P. aeruginosa was only 20%. Staphylococcus aureus was more resistant to iodine (40% sensitivity) compared to P. aeruginosa, which was 100% sensitive to iodine.

Abbreviations: FDA, Food and Drug Administration; MDR, multidrug-resistant; MRSA, methicillin-resistant Staphylococcus aureus; P. aeruginosa, Pseudomonas aeruginosa; S. aureus, Staphylococcus aureus.

Citation: AL-Khikani F, Ayit A. The Antibacterial Action of Safranin and Gentian Violet. Rambam Maimonides Med J 2022;13(3):e0018. doi:10.5041/RMMJ.10475

Copyright: © 2022 AL-Khikani and Ayit. This is an open-access article. All its content, except where otherwise noted, is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Conflict of interest: No potential conflict of interest relevant to this article was reported.

* To whom correspondence should be addressed. E-mail: falahgh38@gmail.com
Conclusions: Gentian violet and safranin are low-cost and better tolerated topical agents that have potential for use in dermatological applications. Gentian violet had good antibacterial activity against both Gram-positive and Gram-negative bacteria, making it useful for treating bacterial skin pathogens such as S. aureus and P. aeruginosa especially for MDR bacteria. While safranin has good efficacy against Gram-positive bacteria (S. aureus), its effect against Gram-negative bacteria (e.g. P. aeruginosa) is poor.

KEY WORDS: Antimicrobial agents, dyes, gentian violet, Pseudomonas aeruginosa, safranin, Staphylococcus aureus

INTRODUCTION

The Gram stain, a procedure invented by Hans Christian Gram in 1884, uses differential staining with a gentian violet–iodine complex and a safranin counterstain to discriminate between Gram-positive and Gram-negative bacteria. After being exposed to alcohol, the cell walls of Gram-positive organisms maintain this complex and look purple, whereas the cell walls of Gram-negative organisms decolorize and become pink.1

 Throughout the first half of the twentieth century, gentian violet was widely adopted for use in a variety of diseases including trench mouth, thrush, impetigo, burns, pinworm, and cutaneous and systemic fungal infections.2–3 Claims of gentian violet efficacy during this time period are difficult to ascertain, given that the composition of gentian violet dyes varied and the authors did not always describe the precise solutions used in their publications. Its use lost popularity with physicians with the discovery and mass manufacture of sulfa medicines and penicillin in the 1940s, and scientific research shifted to the development of novel antibiotic families. However, with the rise of antibiotic resistance there has been a recent resurgence of interest in gentian violet treatment for anti-sepsis and other purposes. Recent research on its mechanisms of action has broadened its potential use in dermatology. Gentian violet is widely accessible, affordable, and simple to use, with few negative effects.

Gentian violet seems to have two unique modes of action that contribute to its therapeutic use. It inhibits the NADPH oxidase complex, which includes Nox1,2, and 4, in mammalian cells, resulting in decreased superoxide generation. Gentian violet can form a covalent adduct with thioredoxin-2 (TRX-2) in bacteria, fungi, and parasites. The discovery that gentian violet inhibits NADPH oxidase revealed the effect of gentian violet on both host and pathogenic organisms, which could be leveraged to improve anti-angiogenesis and tumor immunity in the twenty-first century.4 Antibacterial, antifungal, antihelminthic, antitrypanosomal, antiangiogenic, and anticancer activities are all found in gentian violet.5,6 Burn wounds are treated with gentian violet in resource-constrained circumstances.7 Gentian violet’s long history of topical and systemic usage, especially in the prevention of illness, as well as its stability—particularly at room temperature for long periods of time—has made it a cornerstone of dermatologic therapy in developing nations. Several considerations, including the rise of antibiotic resistance and the widespread use of catheters and indwelling devices, imply that gentian violet should be used more widely in industrialized countries as well.

Initial studies performed with mice showed an increased rate of hepatocellular carcinoma in mice fed large doses of 300 to 600 parts per million gentian violet.8 Despite nearly a century of use, not a single case of cancer has been definitively associated with gentian violet use.9

Safranin (also referred to as safranin O or basic red 2), a less expensive and safer plant histology stain, could potentially be utilized for human tissues since it provides equivalent or better accuracy in the diagnosis of frozen sections of basal and squamous cell carcinomas.10

The biological stain safranin is used in histology and cytology. Certain staining techniques utilize it as a counterstain, turning cell nuclei red. In both Gram and endospore staining, this is the standard counterstain. It may be used to identify cartilage, mucin, and mast cell granules, among other things.11

In light of the recent emergence of a significant incidence of bacterial resistance, repurposing of these antimicrobial medicines merits serious consideration.12–14 To that end this study tested the antibacterial efficacy of gentian violet and safranin against the multidrug-resistant organisms Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa).
MATERIALS AND METHODS

Both *S. aureus* and *P. aeruginosa* are commonly encountered pathogens in wounds. Hence, clinical isolates from patient wounds or abscesses were obtained following receipt of verbal informed consent. For the purposes of this study, we selected 20 isolates: 10 Gram-positive *S. aureus* isolates from abscesses, and 10 Gram-negative *P. aeruginosa* isolates from abscesses and wound swabs. The VITEK 2 automated system (bioMérieux, Marcy-l’Étoile, France) was used to identify bacterial pathogens after growth on artificial media.

**Dye Preparation**

Gentian violet stock solution was prepared by dissolving 20 g of crystal violet in 100 mL ethanol. To create an oxalate stock solution, 1 g of ammonium oxalate was dissolved in 100 mL water. The working solution was made up of 1 mL crystal violet stock solution, 10 mL water, and 40 mL of oxalate stock solution, which was stored in a drop vial. The final concentration was gentian violet 0.2%

The stock solution of safranin was created by dissolving 2.5 g of safranin in 100 mL of 95% ethanol. The working solution was one part stock solution in five parts water. The final concentration was safranin 0.025%

**Antibacterial Activity Screening**

Standard agar well diffusion was used to determine the antibacterial activity *in vitro*. Petri-dishes were prepared with ~25 mL of autoclaved nutritional agar poured onto sterile plates and allowed to set. The surface of each plate was then drilled with a sterile cork borer (6 mm) and three wells punched out. A total of 50 µL of standardized test organism culture (adjusted to 0.5 McFarland 107 CFU/mL) was placed on the agar plate. The wells were then filled with 50 µL of dye; 50 µL of iodine was used as a positive control. The seeded Petri-dishes were incubated at 37°C for 24 hours before measuring the inhibition zone. Calculations of zone inhibition were made according to the Clinical and Laboratory Standards Institute: weak antibacterial activity, zone <10 mm; moderate antibacterial activity, zone 10–13 mm; strong antibacterial activity, zone >13 mm.²⁴,²⁵

Ceftriaxone (30 mg), ceftazidime (30 mg), cefotaxime (30 mg), gentamicin (10 mg), amikacin (30 mg), ciprofloxacin (5 mg), imipenem (10 mg), penicillin (10 mg), erythromycin (15 mg), trimethoprim/sulfamethoxazole (25 mg), vancomycin (30 mg), and meropenem (10 mg) were tested for antimicrobial susceptibility using Kirby–disc-diffusion Bauer’s technique (10 mg). Bacteria were classified as multidrug-resistant (MDR) if they were resistant to more than two classes of antibiotics.

**Data Analysis**

For both *S. aureus* and *P. aeruginosa*, the numbers of clinical isolates showing weak, moderate, and strong activity were noted. For statistical analysis, SPSS software 14.0 (SPSS Inc., Chicago, IL, USA) was used. Differences in the rate of strong activity between iodine, gentian violet, and safranin were evaluated using chi-square test for independence. Differences between the radii of the zones of inhibition were analyzed with the Mann–Whitney test.

**Ethics**

This study was approved by the Ethical Committee of the Babylon Health Directorate (June 3, 2021; #37815). Before collecting samples, patients or their parents (if the patient was a minor) provided verbal consent. Standard health and safety precautions were followed when acquiring the samples.

**RESULTS**

Ten Gram-positive *S. aureus* isolates from abscesses and 10 Gram-negative *P. aeruginosa* isolates collected from pus and wound specimens were analyzed. All of the isolates were MDR (Table 1).

Both gentian violet and safranin showed strong antibacterial activity against all of the tested *S. aureus* isolates (Table 2). Both gentian violet and safranin fared better compared to iodine, which showed strong antibacterial activity in only five of the 10 *S. aureus* isolates (*P*<0.003). The median (IQR) radius of the zone of inhibition was 24 mm (21.75–25.75 mm) for gentian violet and 18 mm (17–20.25 mm) for safranin. There was a significant difference between the radii of the zones of inhibition created by the two stains (*P*<0.001).

Unlike the case of *S. aureus*, only gentian violet and iodine showed strong antibacterial activity against all 10 *P. aeruginosa* isolates tested (Table 2). Compared to gentian violet and iodine, only two of the 10 *P. aeruginosa* isolates proved to be sensitive to safranin (*P*<0.001). The median (IQR) radius of the zone of inhibition was 21.5 mm (16–26.25 mm) for gentian violet and 21 mm (18.75–24.5 mm) for iodine. The difference between the radii of the zones of inhibition created by the two stains was not significant (*P*<0.001).
DISCUSSION

This study found that gentian violet has a high rate of effectiveness against both Gram-positive and Gram-negative bacteria. Bakker et al. had already explored gentian violet as an antimicrobial for dermatological illness in 1992. After using gentian violet and a similar triphenylmethane dye to stain five bacterial species (∗Streptococcus A and B, Proteus, P. aeruginosa, and S. aureus) and Candida albicans, a low critical concentration of gentian violet was shown to be very efficient against Candida, Streptococcus, and Staphylococcus species; it was also moderately effective against Gram-negative bacteria.

Because of its ability to penetrate the bacterial cell wall and covalently link to proteins, gentian violet is very efficient against Gram-positive bacteria. Due to its inability to permeate the lipids surrounding the cell membrane, gentian violet is significantly less efficient against Gram-negative bacteria and Mycobacterium. The Gram stain, which has been in clinical use for over a century, is based on this principle.4

In one study, researchers separated 38 consecutive individuals with acute eczema colonized with S. aureus into three treatment groups; only gentian violet 0.3% had any anti-Staphylococcus efficacy in vitro. Gentian violet was also observed to dramatically reduce S. aureus density in both afflicted and unaffected skin after 4 days, as well as the clinical severity of eczema.9 Gentian violet has also been shown to be less efficient against Gram-negative bacteria in early trials.20 It destroys Pseudomonas biofilms in vitro, according to a recent study.21

In the largest study of its kind, conducted by the United States Food and Drug Administration (FDA), large doses of gentian violet were fed to rats over their lifetime. After 2 years, an increase in thyroid cancer was seen.22 Given that gentian violet is a nicotinamide adenine dinucleotide phosphate oxidase inhibitor, it most likely also inhibits the structurally similar thyroid peroxidase, causing hypothyroidism and feedback stimulation of thyroid-stimulating hormone from the pituitary gland, causing the replication of thyroid cells.23 In early attempts to treat bacterial sepsis, and as an antiprotozoal for strongyloidiasis and Chagas disease, humans were exposed to systemic doses of gentian violet, which was effective in treating these diseases.4 Therefore, while gentian violet is not free of side effects, researchers believe that topical gentian violet is safe for use in humans.9

In addition to its excellent recycling abilities, the pseudo-first order and intraparticle diffusion models play a role in the process of gentian violet adsorption resulting in a strong inhibitory effect on Escherichia coli growth.24 Gentian violet has been used to successfully treat MRSA in otitis media25 as well

| Antibiotics          | Pseudomonas aeruginosa (Resistance %) | Staphylococcus aureus (Resistance %) |
|----------------------|--------------------------------------|--------------------------------------|
| Amikacin             | 50%                                  | 60%                                  |
| Amoxicillin          | 100%                                 | 100%                                 |
| Cefotaxime           | 80%                                  | 100%                                 |
| Ceftazidime          | 90%                                  | 90%                                  |
| Ceftriaxone          | 80%                                  | 90%                                  |
| Ciprofloxacin        | 60%                                  | 70%                                  |
| Erythromycin         | 100%                                 | 80%                                  |
| Gentamicin           | 90%                                  | 50%                                  |
| Imipenem             | 50%                                  | 30%                                  |
| Meropenem            | 50%                                  | 30%                                  |
| Penicillin           | 100%                                 | 100%                                 |
| Trimethoprim/Sulfamethoxazole | 100%               | 80%                                  |
| Vancomycin           | 100%                                 | 50%                                  |
as nasal carriage of MRSA outside of dermatology.\textsuperscript{26} Hence, it is again emerging as a viable therapy option for MRSA infections in light of rising prevalence and evolving resistance to current medicines.

Our study found safranin to be 100\% effective against Gram-positive bacteria (\textit{S. aureus}), but it had only 20\% efficacy against Gram-negative bacteria (\textit{Pseudomonas A}). Only a few studies have looked at safranin’s antibacterial activity against microorganisms. Photodynamic therapy with safranin had a pronounced antibacterial effect on \textit{Fusobacterium nucleatum} and \textit{Porphyromonas gingivalis}, and \textit{Streptococcus gordonii} was fully eradicated.\textsuperscript{27} Although gentian violet staining is routinely used to quantify biofilm growth, it has been linked to toxicity. Safranin, on the other hand, is a non-toxic stain that may be utilized in clinical settings to safely treat a variety of diseases.\textsuperscript{28}

### Table 2. The Inhibition Zones (in mm) for Gentian Violet, Safranin, and Control (Iodine) Dyes in All 20 Samples.

| Bacteria                    | Gentian Violet | Safranin | Iodine |
|-----------------------------|----------------|----------|--------|
| \textit{Staphylococcus aureus} | 25             | 20       | 17     |
| \textit{Staphylococcus aureus} | 23             | 17       | 12     |
| \textit{Staphylococcus aureus} | 21             | 20       | 13     |
| \textit{Staphylococcus aureus} | 22             | 18       | 12     |
| \textit{Staphylococcus aureus} | 23             | 17       | 15     |
| \textit{Staphylococcus aureus} | 25             | 18       | 17     |
| \textit{Staphylococcus aureus} | 21             | 18       | 11     |
| \textit{Staphylococcus aureus} | 25             | 17       | 17     |
| \textit{Staphylococcus aureus} | 29             | 21       | 15     |
| \textit{Staphylococcus aureus} | 28             | 22       | 11     |
| \textit{Pseudomonas aeruginosa} | 26             | 0        | 26     |
| \textit{Pseudomonas aeruginosa} | 16             | 0        | 22     |
| \textit{Pseudomonas aeruginosa} | 16             | 0        | 26     |
| \textit{Pseudomonas aeruginosa} | 19             | 0        | 20     |
| \textit{Pseudomonas aeruginosa} | 27             | 18       | 18     |
| \textit{Pseudomonas aeruginosa} | 28             | 0        | 24     |
| \textit{Pseudomonas aeruginosa} | 21             | 18       | 19     |
| \textit{Pseudomonas aeruginosa} | 22             | 0        | 20     |
| \textit{Pseudomonas aeruginosa} | 15             | 0        | 17     |
| \textit{Pseudomonas aeruginosa} | 23             | 0        | 22     |

Inhibition zones: Weak \(<10\) mm; moderate \(10-13\) mm; strong \(>13\) mm.

### CONCLUSIONS

The increasing prevalence of MDR bacteria is a major concern worldwide. This study highlights the significant antibacterial activity of some dyes, specifically gentian violet and safranin, against MDR pathogens. The results support the potential for using these dyes to manage patients in order to control the spread of MDR pathogens and the nosocomial infections in hospitals, particularly for abscess and wound infections, which can be treated topically, making them safer to use.

Gentian violet is potentially useful for treating bacterial abscess or wounds for both Gram-positive and Gram-negative bacteria, especially those with MDR isolates. Safranin would be useful for treating Gram-positive bacteria such as \textit{S. aureus}, but is much less effective against Gram-negative bacteria.
This study also found that iodine has greater efficacy against Gram-negative bacteria compared to Gram-positive bacteria, which may be highly iodine-resistant.

REFERENCES

1. Coico R. Gram staining. Curr Portoc Microbiol 2005; Appendix 3:A–3C. CrossRef
2. Bumbalo TS, Gustina FJ. The treatment of pinworm infection (enterobiasis) with gentian violet suspension. J Pediatr 1955;47:311–14. CrossRef
3. Sanderson ES, Smith DC. The effect of gentian violet on the organism of blastomycotic infection. Arch Derm Syphilol 1927;16:153–5. CrossRef
4. Maley AM, Arbiser JL. Gentian violet: a 19th century drug re-emerges in the 21st century. Exp Dermatol 2013;22:775–80. CrossRef
5. Docampo R, Moreno SN. The metabolism and mode of action of gentian violet. Drug Metab Rev 1990;22:161–78. CrossRef
6. Woo KY, Alam T, Marin J. Topical antimicrobial tool-kit for wound infection. Surg Technol Int 2014;25:45–52. PMID: 25433174
7. Choudhary KN, Soni PP, Sao DK, Murthy R, Deshkar AM, Nanda BR. Role of gentian violet paint in burn wound management: a prospective randomised control trial. J Indian Med Assoc 2013;111:248–50. PMID: 24475556
8. Littlefield NA, Blackwell BN, Hewitt CC, Gaylor DW. Chronic toxicity and carcinogenicity studies of gentian violet in mice. Fundam Appl Toxicol 1985;5:902–12. CrossRef
9. Arbiser JL. Gentian violet is safe. J Am Acad Dermatol 2009;61:359. CrossRef
10. Tran D, Golick M, Rabinovitz H, Rivlin D, Elgart G, Nordlow B. Hematoxylin and safranin O staining of frozen sections. Dermatol Surg 2000;26:1979. CrossRef
11. Rosenberg L. Chemical basis for the histological use of safranin O in the study of articular cartilage. J Bone Joint Surg Am 1971;53:69–82. PMID: 4250366
12. AL-Khikani FH. Pulmonary mycoses treated by topical amphotericin B. Biomedical and Biotechnology Research Journal (BBRJ) 2020;4:123–6.
13. AL-Khikani FH, Almosawey HA, Abdullah YJ, et al. Potential antiviral properties of antifungal drugs. Journal of the Egyptian Women’s Dermatologic Society 2020;17:185–6. CrossRef
14. AL-Khikani FH. Amphotericin B from antifungal to antiviral therapy: promising modern therapeutic branch. Research Results in Pharmacology 2020;6:57–65. CrossRef
15. Finegold SM, Martin WJ. Cultivation of Pathogenic Microorganisms from Clinical Material. In: Finegold SM, Martin WJ, Bailey WR, eds. Bailey and Scott’s Diagnostic Microbiology, 6th ed. St. Louis, MO, USA: CV Mosby Co; 1982:81–91.
16. Ogu GI, Tanimowo WO, Nwachukwu PU, Igere BE. Antimicrobial and phytochemical evaluation of the leaf, stem bark and root extracts of Cyathula prostrata (L) Blume against some human pathogens. J Intercell Ethnopharmacol 2012;1:32–43. CrossRef
17. Naz R, Bano A. Antimicrobial potential of Ricinus communis leaf extracts in different solvents against pathogenic bacterial and fungal strains. Asian Pac J Trop Biomed 2012;2:944–7. CrossRef
18. Bakker P, Van Doorne H, Gooskens V, Wieringa NF. Activity of gentian violet and brilliant green against some microorganisms associated with skin infections. Int J Dermatol 1992;31:210–13. CrossRef
19. Brockow K, Grabenhorst P, Abeck D, et al. Effect of gentian violet, corticosteroid and tar preparations in Staphylococcus aureus colonized atopic eczema. Dermatology 1999;199:231–6. CrossRef
20. Churchman JW. The selective bactericidal action of gentian violet. J Exp Med 1912;16:221–47. CrossRef
21. Wang EW, Agostini G, Olomu O, Runco D, Jung JY, Chole RA. Gentian violet and ferric ammonium citrate disrupt Pseudomonas aeruginosa biofilms. Laryngoscope 2008;118:2050–6. CrossRef
22. Littlefield NA, Gaylor DW, Blackwell BN, Allen RR. Chronic toxicity/carcinogenicity studies of gentian violet in Fischer 344 rats: two-generation exposure. Food Chem Toxicol 1989;27:239–47. CrossRef
23. Perry BN, Govindarajan B, Bhandarkar SS, et al. Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol 2006;126:2316–22. CrossRef
24. Abu Elella MH, Sabaa MW, ElHafeez EA, Mohamed RR. Crystal violet dye re-use with crosslinked grafted xanthan gum. Int J Biol Macromol 2019;137:1086–101. CrossRef
25. Kayama C, Goto Y, Shimoya S, et al. Effects of gentian violet on refractory discharging ears infected with methicillin-resistant Staphylococcus aureus. J Otolaryngol 2006;35:384. CrossRef
26. Okano M, Noguchi S, Tabata K, Matsumoto Y. Topical gentian violet for cutaneous infection and nasal carriage with MRSA. Int J Dermatol 2000;39:942–4. CrossRef
27. Voos AC, Kranz S, Tonndorf-Martini S, et al. Photodynamic antimicrobial effect of safranine O on an ex vivo periodontal biofilm. Lasers Surg Med 2014;46:235–43. CrossRef
28. Ommen P, Zobek RL. Quantification of biofilm biomass by staining: non-toxic safranin can replace the popular crystal violet. J Microbiol Methods 2017;141:87–9. CrossRef